S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17
S&P 500   4,088.85
DOW   32,654.59
QQQ   306.17

Protagonist Therapeutics (PTGX) Stock Forecast, Price & News

+0.02 (+0.23%)
(As of 05/17/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.75 million shs
Average Volume
1.01 million shs
Market Capitalization
$418.93 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive PTGX News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagonist Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Protagonist Therapeutics logo

About Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$27.36 million
Book Value
$6.29 per share


Net Income
$-125.55 million
Net Margins
Pretax Margin




Free Float
Market Cap
$418.93 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.53 out of 5 stars

Medical Sector

1022nd out of 1,426 stocks

Pharmaceutical Preparations Industry

509th out of 680 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Protagonist Therapeutics (NASDAQ:PTGX) Frequently Asked Questions

Is Protagonist Therapeutics a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protagonist Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Protagonist Therapeutics stock.
View analyst ratings for Protagonist Therapeutics
or view top-rated stocks.

Are investors shorting Protagonist Therapeutics?

Protagonist Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 3,290,000 shares, an increase of 20.5% from the April 15th total of 2,730,000 shares. Based on an average daily volume of 1,050,000 shares, the days-to-cover ratio is presently 3.1 days.
View Protagonist Therapeutics' Short Interest

When is Protagonist Therapeutics' next earnings date?

Protagonist Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Protagonist Therapeutics

How were Protagonist Therapeutics' earnings last quarter?

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) released its quarterly earnings data on Monday, February, 28th. The company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.02. The business earned $8.62 million during the quarter, compared to the consensus estimate of $7.38 million. Protagonist Therapeutics had a negative net margin of 261.21% and a negative trailing twelve-month return on equity of 37.22%.
View Protagonist Therapeutics' earnings history

What price target have analysts set for PTGX?

8 analysts have issued twelve-month price objectives for Protagonist Therapeutics' shares. Their forecasts range from $35.00 to $70.00. On average, they anticipate Protagonist Therapeutics' share price to reach $50.63 in the next twelve months. This suggests a possible upside of 488.0% from the stock's current price.
View analysts' price targets for Protagonist Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Protagonist Therapeutics' key executives?
Protagonist Therapeutics' management team includes the following people:
  • Dr. Dinesh V. Patel Ph.D., CEO, Pres, Sec. & Director (Age 65, Pay $1.04M)
  • Dr. David Y. Liu Ph.D., Chief R&D Strategy Officer (Age 72, Pay $702.87k)
  • Dr. Suneel K. Gupta Ph.D., Chief Devel. Officer (Age 63, Pay $698.72k)
  • Dr. Richard S. Shames, Clinical Advisor (Age 62)
  • Mr. Asif Ali, Exec. VP & Chief Financial Officer
  • Mr. Mohammad Masjedizadeh, Exec. VP & CTO
  • Mr. Matthew M. Gosling, Exec. VP & Gen. Counsel (Age 51)
  • Ms. Carena Spivey, Exec. Director of HR
  • Dr. Ashok Bhandari Ph.D., Sr. VP of Discovery Chemistry & Process Research (Age 58)
  • Dr. Scott Eric Plevy M.D., Exec. VP and Therapeutic Head of Gastroenterology
What other stocks do shareholders of Protagonist Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagonist Therapeutics investors own include VBI Vaccines (VBIV), Viking Therapeutics (VKTX), ImmunoGen (IMGN), SCYNEXIS (SCYX), Energy Transfer (ET), Strongbridge Biopharma (SBBP), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

When did Protagonist Therapeutics IPO?

(PTGX) raised $70 million in an IPO on Thursday, August 11th 2016. The company issued 5,800,000 shares at $11.00-$13.00 per share. Leerink Partners, Barclays and BMO Capital Markets served as the underwriters for the IPO.

What is Protagonist Therapeutics' stock symbol?

Protagonist Therapeutics trades on the NASDAQ under the ticker symbol "PTGX."

Who are Protagonist Therapeutics' major shareholders?

Protagonist Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include RTW Investments LP (9.85%), State Street Corp (6.69%), BlackRock Inc. (6.67%), Vanguard Group Inc. (4.79%), Farallon Capital Management LLC (2.33%) and Dimensional Fund Advisors LP (1.77%). Company insiders that own Protagonist Therapeutics stock include David Y Liu, Dinesh V Ph D Patel and Sarah B Noonberg.
View institutional ownership trends for Protagonist Therapeutics

Which major investors are selling Protagonist Therapeutics stock?

PTGX stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Artal Group S.A., Rothschild & Co. Asset Management US Inc., Citigroup Inc., Walleye Capital LLC, J. Goldman & Co LP, BlackRock Inc., and HAP Trading LLC. Company insiders that have sold Protagonist Therapeutics company stock in the last year include David Y Liu, and Dinesh V Ph D Patel.
View insider buying and selling activity for Protagonist Therapeutics
or view top insider-selling stocks.

Which major investors are buying Protagonist Therapeutics stock?

PTGX stock was bought by a variety of institutional investors in the last quarter, including RTW Investments LP, State Street Corp, Fairmount Funds Management LLC, Sessa Capital IM L.P., Goldman Sachs Group Inc., Affinity Asset Advisors LLC, Deep Track Capital LP, and Lord Abbett & CO. LLC.
View insider buying and selling activity for Protagonist Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Protagonist Therapeutics?

Shares of PTGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protagonist Therapeutics' stock price today?

One share of PTGX stock can currently be purchased for approximately $8.61.

How much money does Protagonist Therapeutics make?

Protagonist Therapeutics has a market capitalization of $418.93 million and generates $27.36 million in revenue each year. The company earns $-125.55 million in net income (profit) each year or ($2.590010) on an earnings per share basis.

How many employees does Protagonist Therapeutics have?

Protagonist Therapeutics employs 118 workers across the globe.

What is Protagonist Therapeutics' official website?

The official website for Protagonist Therapeutics is www.protagonist-inc.com.

How can I contact Protagonist Therapeutics?

Protagonist Therapeutics' mailing address is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. The company can be reached via phone at (510) 474-0170 or via email at [email protected].

This page was last updated on 5/18/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.